Preparation of PPy/TiO2 core-shell nanorods film and its photocathodic protection for 304 stainless steel under visible light

Yunpeng Liu(Shenyang Institute of Automation), Zijun Ren(Xi'an Jiaotong University), Chengcheng Zhao(Xi'an Jiaotong University), Hao Xu(Xi'an Jiaotong University), Hui Wang(Dali University), Wei Yan(Xi'an Jiaotong University), Xi Wang(Nanjing Agricultural University), Xuyang Zhao(Xi'an Jiaotong University), Jiangtao Feng(Xi'an Jiaotong University)
Materials Research Bulletin
December 23, 2019
10.1016/j.materresbull.2019.110751
Cited by 35

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412